Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate

strong correlation with clinical and parasitological infection across seasons and transmission

settings in The Gambia

Author details

Lindsey Wu[1*], Julia Mwesigwa[2], Muna Affara[3], Mamadou Bah[2], Simon Correa[2], Tom Hall[4], James

Beeson[5], Kevin K.A. Tetteh[1], Immo Kleinschmidt[6,7], Umberto D'Alessandro[2], Chris Drakeley[1]

*Corresponding author: lindsey.wu@lshtm.ac.uk

1. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Infectious Tropical Diseases,

Department of Infection Biology. London WC1E 7HT, UK.

2. Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine.

Fajara, The Gambia.

3. Bernhard Nocht Institute for Tropical Medicine (BNITM). Arusha, Tanzania.

4. St. George's University of London (SGUL). London, United Kingdom.

5. Burnet Institute. Melbourne, Australia.

6. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Epidemiology and Population

Health, Department of Infectious Disease Epidemiology. London WC1E 7HT, UK.

7. School of Pathology, Wits Institute for Malaria Research, Faculty of Health Science, University of

Witwatersrand, South Africa.

Email addresses:

LW: lindsey.wu@lshtm.ac.uk

JM: julia.mwesigwa@lshtm.ac.uk

MA: affara@bnitm.de

MB: mmbah@mrc.gm

SC: scorea@mrc.gm

TH: thall@sgul.ac.uk

JB: beeson@burnet.edu.au

KKAT: kevin.tetteh@lshtm.ac.uk

IK: immo.kleinschmidt@lshtm.ac.uk

UD: umberto.dalessandro@lshtm.ac.uk

CD: chris.drakeley@lshtm.ac.uk

Keywords: malaria, serology, surveillance

Abstract

Background

As malaria transmission declines, sensitive diagnostics are needed to evaluate interventions and

monitor transmission. Serological assays measuring malaria antibody responses offer a cost-effective

detection method to supplement existing surveillance tools.

Methods

A prospective cohort study was conducted from 2013 to 2015 in 12 villages across five administrative

regions in The Gambia. Serological analysis included samples from the West Coast Region at the start

and end of the season (July and December 2013) and from the Upper River Region in July and

December 2013, and April and December 2014. Antigen-specific antibody responses to seven

Plasmodium falciparum (P.falciparum) antigens – Etramp5.Ag1, GEXP18, HSP40.Ag1, Rh2.2030,

EBA175 RIII-V, *Pf*MSP1$_{19}$, *Pf*AMA1 - were quantified using a multiplexed bead-based assay. The

association between antibody responses and clinical and parasitological endpoints was estimated at

the individual, household, and population level.

Results

Strong associations were observed between clinical malaria and concurrent sero-positivity to Etramp5.Ag1 (aOR 4.56 95%CI 2.94 – 7.06), PfMSP1$_{19}$ (aOR 3.84 95%CI 2.41 – 6.04) and PfAMA1 (aOR 2.18 95%CI 1.23 – 3.84), while asymptomatic infection was associated with sero-positivity to all antigens. Village-level sero-prevalence amongst children 2-10 years against Etramp5.Ag1, HSP40.Ag1, and PfMSP1$_{19}$ showed the highest correlations with clinical and *P.falciparum* infection incidence rates. For all antigens, there was increased odds of asymptomatic *P.falciparum* infection in subjects residing in a compound with greater than 50% sero-prevalence, with a 2- to 3-fold increase in odds of infection associated with Etramp5.Ag1, GEXP18, Rh2.2030, PfMSP1$_{19}$ and PfAMA1. For individuals residing in sero-positive compounds, the odds of clinical malaria were reduced, suggesting a protective effect.

Conclusions

At low transmission, long-lived antibody responses could indicate foci of malaria transmission that have been ongoing for several seasons or years. In settings where sub-patent infections are prevalent and fluctuate below the detection limit of polymerase chain reaction (PCR), the presence of short-lived antibodies may indicate recent infectivity, particularly in the dry season when clinical cases are rare. Serological responses may reflect a persistent reservoir of infection, warranting community-targeted interventions if individuals are not clinically apparent but have the potential to transmit. Therefore, serological surveillance at both the individual and household level may be used to target interventions where there are foci of asymptomatically infected individuals.

Background

As malaria transmission declines, the prevalence of infection becomes increasingly heterogeneous

and focal. In low transmission settings, highly sensitive diagnostics are needed to measure subtle

changes in malaria incidence, evaluate the effectiveness of community-based interventions, and

monitor potential re-introduction after elimination. Evidence suggests that infections below the

detection limit of microscopy and rapid diagnostic tests (RDTs) contribute to on-going transmission,

but the magnitude of their public health importance is yet to be determined.[1–3] Nucleic acid

amplification tests (NAATs), such as ultrasensitive quantitative polymerase chain reaction (qPCR), can

detect less than 1 parasite per microlitre[4,5], but are still sensitive to fluctuations in parasite density

during the course of an infection.

Serological assays measuring antibody responses may be a more stable diagnostic alternative, offering

a cost-effective detection method to supplement existing surveillance tools. A number of studies in

The Gambia have observed spatiotemporal variations in antibody responses to malaria over time[6,7],

with similar observations in Tanzania[8], Equatorial Guinea[9], and South Africa[10]. Newly developed

serological markers of recent exposure to malaria may now be capable of measuring short-term

changes in malaria transmission over periods as short as 1-2 years. However, these markers require

validation with population-representative data from a range of endemic settings[11,12]. Longitudinal

cohort studies provide a unique opportunity for a multi-metric assessment of transmission dynamics

using clinical, parasitological, and serological endpoints. The aim is to understand the relative accuracy

of different diagnostics and their utility in epidemiological surveillance.

Using a suite of novel serological markers of malaria exposure, this study determines the correlation

of antibody responses with clinical and parasitological endpoints at the individual, household, and

population level in four villages in rural Gambia over two years, estimating the strength of association

between serological markers and gold standard metrics of malaria infection. These findings will

support the utility of serology in measuring recent malaria transmission and allow selection of markers

most suitable for use in future surveillance, particularly for reactive detection strategies in elimination

settings.

Methods

Data and sampling

A prospective cohort study was conducted from 2013 to 2015 in 12 villages across five administrative

regions - West Coast (WCR), North Bank (NBR), Lower River (LRR), Central River (CRR) and Upper River

(URR) Regions. *Plasmodium falciparum* (*Pf)* prevalence measured by polymerase chain reaction (PCR)

ranged from 2.27 to 19.60% in the Central River and Upper River Regions respectively (Figure 1). As

described by Mwesigwa et al,[13] the study aim was to understand the dynamics of malaria infection

and the impact of annual mass drug administration (MDA). Residents more than six months of age

were enrolled in the study, and monthly surveys were conducted during malaria transmission season

from June to December each year, as well as surveys in the dry season in April 2014, and prior to the

implementation of MDA in May and June 2014 and 2015.

Individual finger prick blood samples were collected for haemoglobin estimation and on filter paper

(Whatman 3 Corporation, Florham Park, NJ, USA) for molecular and serological analysis. Clinical

malaria cases were identified by passive case detection (PCD) at health facilities or in villages by study

nurses in individuals with history of fever in the previous 24 hours or axillary temperature $\geq 37.5^{o}$C

and a positive Rapid Diagnostic Test (RDT) result (Paracheck *Pf*, Orchid Biomedical System, India).

Serological analysis included all available samples from the West Coast Region in Besse and N'Demban

villages from surveys conducted at the start of the transmission season in July 2013 (N=537) and at

the end of the season in December 2013 (N=526). In the Upper River Region, analysis included all

samples collected in Njaiyal and Madino Samako in July 2013 (N=779), December 2013 (N=632), April

(dry season) 2014 (N=823), and December 2014 (N=757) (Figure 1, Table 1). These regions represent

extremes of two transmission intensities, with months selected at the start and end of the

transmission season. Samples from clinical PCD cases were linked by study participant identification

code to samples from the same individuals collected during routine monthly surveys.

This study was approved by the Gambia Government/MRC Joint Ethics Committee (SCC1318). Verbal

consent was first obtained at village sensitisation meetings, followed by individual written informed

consent for all participants. Parents/guardians provided written consent for children less than

17 years, and assent was obtained from children between 12 and 17 years.

Laboratory procedures

Antigen-specific antibody responses were quantified using the Luminex MAGPIX protocol described in

Wu et al 2019.[14] Plasma was eluted from 6mm dried blood spots (DBS) (4 µl whole blood equivalent)

and shaken overnight at room temperature in 200 µl of protein elution buffer containing phosphate

buffered saline (PBS) (pH 7.2), 0.05% sodium azide and 0.05% Tween-20, yielding an initial 1:50 sample

dilution. One day prior to assay processing, samples were diluted to a final 1:500 dilution using 10 µl

of the 1:50 pre-dilution sample and 90 µl of blocking Buffer B to prevent non-specific binding (1xPBS,

0.05% Tween, 0.5% bovine serum albumin (BSA), 0.02% sodium azide, 0.1% casein, 0.5% polyvinyl

alcohol (PVA), 0.5% polyvinyl pyrrolidone (PVP) and 1,500 µg/ml *E.coli* extract). Negative and positive

controls were also incubated one day prior in Buffer B, with negative controls prepared at a 1:500

dilution and Gambian pooled positive controls in a 6-point 5-fold serial dilution (1:10-1:31,250). The

positive control was based on a pool of 22 serum samples from malaria hyper-immune individuals in

The Gambia, and ten individual plasma samples from European malaria-naive adults were used as

negative controls.

Samples were prepared for diagnostic PCR as described by Mwesigwa et al 2017.[13] Briefly, DNA was

extracted from three 6-mm DBS using the automated QIAxtractor robot (Qiagen). Negative and

positive (3D7) controls were included to control for cross contamination and DNA extraction

efficiency, respectively. The DBS were lysed by incubation in tissue digest buffer at 60 °C for 1 hour

and digested eluates were applied onto capture plates, washed, and the DNA eluted into 80 µl. The

extracted DNA (4 μl) was used in a nested PCR, amplifying the multi-copy *Plasmodium* ribosomal RNA

gene sequences using genus and species specific primers.[15] All PCR products were run using the

QIAxcel capillary electrophoresis system (Qiagen), using the screening cartridge and 15-1,000 bp-

alignment marker. Results were exported and double scored using both the QIAxcel binary scoring

function and manually by visualization of the gel images and discrepancies were scored by a third

independent reader. All readers were blinded to participant survey data.

Statistical analyses

Data analysis was based on total immunoglobulin (IgG) levels to five antigens as potential markers of

sero-incidence[16] - early transcribed membrane protein 5 (Etramp5.Ag1), gametocyte export protein

18 (GEXP18), heat shock protein 40 (HSP40.Ag1), erythrocyte binding antigen 175 RIII-V (EBA175),

reticulocyte binding protein homologue 2 (Rh2.2030). Two antigens associated with long-lived

antibody response – *P.falciparum* merozoite surface antigen 1 19-kDa carboxy-terminal region

(PfMSP1$_{19}$) and *P.falciparum* apical membrane antigen 1 (PfAMA1) – were included as a comparison,

both historically used to assess sero-conversion rates over time[8,9] and previously studied in The

Gambia[6,7]. For antigens associated with long-lived antibodies (PfMSP1$_{19}$, PfAMA1), a two-component

Gaussian mixture model was used to define distributions of negative and positive antibody levels,

expressed in units of median fluorescence intensity (MFI). Sero-positivity thresholds were defined as

the mean log MFI values plus two standards deviations of the negative distribution.[17] Mixture models

were estimated using the *'normalmixEM'* function in the *'mixtools'* package v1.0.4 in R version 3.6.1.

For antigens associated with shorter-lived antibodies where statistical evidence of a bimodal

distribution of antibody responses in the population was not strong - Etramp5.Ag1, GEXP18,

HSP40.Ag1, EBA175, Rh2.2030 - the sero-positivity threshold was defined by the mean log MFI plus

three standard deviations of 71 malaria-naïve European blood donors used as negative controls.

Individual-level association between antibody response and the concurrent odds of clinical malaria

(passively detected via the health facility or study nurses in the community) or asymptomatic

P.falciparum infection (actively detected using PCR from monthly survey samples) were assessed using

generalised estimating equations (GEE). Analysis was adjusted for age group (1-5 years, 6-15 years,

and greater than 15 years) and use of long-lasting insecticide treated nets (LLINs) in the last 24 hours

and allowed for clustering at the compound level, where compound is a collection of households

centrally located around a main residence. The magnitude of the association between antibody

response and odds of infection was evaluated for interaction with age group.

Using a GEE model, individual-level odds of clinical malaria or asymptomatic infection was assessed

for association with residence in the same compound as a sero-positive individual. Similarly, the

association between individual odds of infection and compound-level sero-prevalence (<50% or

>50%), was assessed using a mixed-effects generalised linear model adjusted for age group and LLIN

use, with random-effects at the compound-level. To ensure that estimates are not biased by the sero-

prevalence of small compounds, analysis was weighted by the number of individuals in the compound

(whose sero-status was assessed) and only included compounds with at least four individuals. Models

were fit using the 'geeM' and 'lme4' packages in R version 3.14.

Village-level sero-prevalence in July and December 2013 amongst children aged 2-10 years was

compared against all-age clinical and *P.falciparum* infection incidence rates from the same months,

the latter of which were previously reported by Mwesigwa et al[13]. Monthly clinical and *P.falciparum*

infection incidence rates were defined respectively as the number of new clinical cases or *P.falciparum*

infections (PCR-positive individuals who were PCR-negative in the previous monthly survey) divided

by total person-years at risk. This age range was selected to align with other routine surveillance

metrics such as annual parasite index (API) commonly using this age group as a sentinel population.

The strength of the relationship between village-level incidence rates and sero-prevalence for each

antigen was assessed using Pearson's correlation coefficient.

Results

Village-level seroprevalence

Data from 2,005 individuals were available for analysis of antibody responses from 5,581 samples

between June 2013 and December 2014 (Tables 1 and 2). The majority of subjects were female in both

the West Coast (55.0%) and the Upper River (54.3%) Regions, and higher LLIN use in the West Coast

(96.6%) compared to the Upper River Region (46.6%). In the West Coast Region, incidence of *P.*

falciparum was three times higher in December than at the start of the transmission season, and five

times higher in December in the Upper River Region (Table 3). Sero-prevalence amongst 2-10 years

olds in the West Coast Region ranged from 1.4% (95%CI 0.0 - 3.1) for Rh2.2030 in July 2013 (start of

the transmission season) and 13.7% (95%CI 8.9-18.5) for Etramp5.Ag1 in December 2013 (end of

transmission season). In the Upper River Region, sero-prevalence across all antigens was higher,

ranging from 5.1% (95%CI 2.5-7.7) for PfMSP1$_{19}$ in July to 36.1% (95%CI 30.0-42.2) for GEXP18 in

December (Table 3). Sero-prevalence in this age group was highly correlated with both clinical malaria

and *P.falciparum* infection incidence rates (Figure 2, Table 4).

In both regions in July and December 2013, correlations between *P.falciparum* infection rate and sero-

prevalence were strongest for Etramp5.Ag1 (ρ=0.98), HSP40.Ag1 (ρ=0.99), and PfMSP1$_{19}$ (ρ=0.99).

Incidence of clinical malaria had the strongest correlations with Etramp5.Ag1 (ρ=0.98), HSP40.Ag1

(ρ=0.95), and PfMSP1$_{19}$ (ρ=0.97). Correlations with both clinical incidence and *P.falciparum* infection

rates remained high for Etramp5.Ag1 (ρ=0.98 and ρ=0.96, respectively) and PfMSP1$_{19}$ (ρ=0.96 and

ρ=0.98, respectively), but slightly lower for HSP40.Ag1 (ρ=0.85 and ρ=0.81, for clinical incidence and

P.falciparum infection rates respectively), after excluding data from December 2013 from the Upper

River Region as a potential outlier. These correlations are based on few datapoints, with three

observations when excluding URR December 2013.

Individual-level association between clinical malaria, asymptomatic *P.falciparum* infection and

concurrent sero-positivity

The odds of clinical malaria were higher in individuals sero-positive to five (out of seven) of the

antigens analysed (Etramp5.Ag1, GEXP18, Rh2.2030, PfMSP1$_{19}$and PfAMA1) (Figure 3A, Table 5). After

adjusting for age and LLIN use, clinical malaria was associated with concurrent sero-positivity to three

antigens (Etramp5.Ag1, PfMSP1$_{19}$and PfAMA1), while odds of asymptomatic infection were strongly

associated with sero-positivity to all antigens. Amongst individuals sero-positive for Etramp5.Ag1,

there was increased odds of both clinical malaria (aOR 4.56, 95%CI 2.94 – 7.06, p<0.001) and

asymptomatic infection (aOR 3.36, 95%CI 2.75 – 4.11, p<0.001) (Table 5). Association with clinical

malaria was slightly lower in individuals sero-positive for PfMSP1$_{19}$ (aOR 3.82, 95%CI 2.41 - 6.04,

p<0.001) and PfAMA1 (aOR 2.18, 95%CI 1.23 - 3.84, p=0.007). Odds of asymptomatic infection in

individuals sero-positive to GEXP18 (aOR 3.10, 95%CI 2.50 – 3.85, p<0.001), Rh2.2030 (aOR 3.10,

95%CI 2.44 - 3.94, p<0.001) and PfAMA1 (aOR 3.83, 95%CI 2.95 - 4.98, p<0.001) was similar to

Etramp5.Ag1.

Individual-level odds of clinical malaria, asymptomatic infection when residing in compounds with

sero-positive individuals

The odds of clinical malaria were reduced for individuals residing in the same compound with an

individual sero-positive to any of the seven antigens (Figure 3B, Table 6), from an 83% reduction if

residing in the same compound as an individual sero-positive for Etramp5.Ag1 (aOR 0.17, 95%CI 0.03-

0.84, p=0.03) to a 95% reduction if residing in the same compound as someone sero-positive for

PfAMA1 (aOR 0.05, 95%CI 0.01 - 0.47, p=0.009). Conversely, the odds of asymptomatic infection were

positively associated with residing in the same compound as sero-positive individuals for five antigens

(Etramp5.Ag1, GEXP18, Rh2.2030, PfMSP1$_{19,}$ and PfAMA1). Adjusted odds of asymptomatic infection

was nearly 3-fold higher if residing with an individual sero-positive for Etramp5.Ag1 (aOR 2.95, 95%CI

1.66 - 5.24, p<0.001) and for GEXP18 (aOR 2.71, 95%CI 1.58 - 4.63, p<0.001). If residing in a compound

with individuals sero-positive to Rh2.2030, PfMSP1$_{19}$ or PfAMA1, the odds of asymptomatic infection

were all nearly twice as high as individuals living in compounds sero-negative to these antigens (Table

6).

Association between individual-level clinical malaria, asymptomatic infection, and compound sero-prevalence

When stratifying by compound-level sero-prevalence, mean regression estimates found a reduced odds of clinical malaria if residing in compound with sero-prevalence less than 50% for all antigens, and an increased odds of clinical malaria in compounds with greater than 50% sero-prevalence for four antigens (Etramp5.Ag1, GEXP18, HSP40.Ag1, and PfMSP1$_{19}$) (Figure 4A, Supplementary File 2 - Tables S3, S7, S11, S19, and S23). However, these results were not statistically significant. There was strong statistical evidence for increasing odds of asymptomatic infection with increasing compound sero-prevalence for two antigens (Etramp5.Ag1 and PfMSP1$_{19}$) (Figure 4B, Supplementary File 2 - Tables S4, S24), and weaker statistical evidence for increasing odds of asymptomatic infection for HSP40.Ag1 and Rh2.2030 (Supplementary File 2 - Tables S14, S16).

Antigens most associated with increased odds of asymptomatic infection were Etramp5.Ag1, GEXP18 and PfMSP1$_{19}$. For Etramp5.Ag1, aOR 2.61 (95%CI 1.53 - 4.45, p<0.001) in compounds with less than 50% sero-prevalence to an aOR 8.32 (95%CI 5.32 - 13.03, p<0.001) in compound sero-prevalence greater than 50%, compared to sero-negative compounds (Supplementary File 2 - Table S4). For GEXP18, aOR ranged from 2.97 (95%CI 1.47 - 5.99, p=0.002) to 8.80 (95%CI 3.50 - 22.12, p<0.001) (Supplementary File 3 - Table S8). For PfMSP1$_{19}$, aOR ranged from 2.18 (95%CI 1.33 - 3.60, p=0.002) to aOR 9.06 (95%CI 5.16 - 15.89, p<0.001) (Supplementary File 2 - Table S24). For HSP40.Ag1, EBA175, and PfAMA1, statistically strong evidence for increased odds of asymptomatic infection was only observed in compounds with greater than 50% sero-prevalence (Supplementary File 2 - Tables S12, S20, S28).

The spatial distribution of infections at both the start and end of the transmission season (June – July 2013 vs August-December 2013) suggest that clinical and asymptomatic malaria are localised near households with Etramp5.Ag1 sero-positive individuals (Figure 5). There are a number of Etramp5.Ag1 sero-positive households at both the start and during the wet season without concurrent clinical or

asymptomatic infections present. However, this is more pronounced for PfAMA1, where sero-

positivity could reflect a longer history of exposure than Etramp5.Ag1 (Supplementary File 3 - Figure

S2). While there are a limited number of clinical cases between June and July 2013, from August to

December 2013, these cases occur in proximity to households with asymptomatic and Etramp5.Ag1

sero-positive individuals.

Discussion

We investigated the association between antibody responses and clinical and parasitological

endpoints at the individual, compound, and population level in The Gambia. At the individual level,

clinical malaria was highly correlated with concurrent sero-positivity to Etramp5.Ag1, PfMSP1$_{19}$ and

PfAMA1, while asymptomatic infection was correlated with sero-positivity to all antigens included in

this study. The strongest associations were with sero-positivity to Etramp5.Ag1 and PfAMA1. Village-

level sero-prevalence amongst children 2-10 years against antigens Etramp5.Ag1, HSP40.Ag1, and

PfMSP1$_{19}$ showed the highest correlations with clinical incidence and Pf infection rates.

At the compound level, individuals had increased odds of asymptomatic infection when residing in a

compound with greater than 50% sero-prevalence to all antigens, with the highest odds associated

with sero-prevalence to Etramp5.Ag1, GEXP18, and PfMSP1$_{19}$. These results do not imply a causal

relationship between serological responses and clinical outcomes or asymptomatic infection, but

highlight that infected individuals tend to be concurrently sero-positive to most of the serological

markers assessed. There was strong evidence of reduced odds of clinical malaria for individuals

residing in the same compound as an individual sero-positive to any of the antigens, suggesting a

protective effect.

While PfMSP1$_{19}$ and PfAMA1 have been used extensively to measure medium and long-term trends

in transmission intensity, these markers may be less sensitive to changes in transmission at higher

endemicities or to smaller short-term fluctuations due to the rapid acquisition of antibodies and the

long half-life of sero-positivity for many blood-stage antigens.[18–21] Individuals with clinical malaria or

with long-lived antibody responses in low transmission regions of western Gambia could indicate foci

of malaria transmission that have been ongoing for several transmission seasons or years. In areas

where parasite density is low and often missed by RDTs and microscopy, using serological markers

could support targeted interventions to clear or eliminate these residual reservoirs of human

infection. Antigens in this study associated with shorter-lived sero-positivity (Etramp5.Ag1, GEXP18,

and HSP40.Ag1) were positively correlated with either clinical malaria and asymptomatic infection,

and sometimes both. These antigens have been relatively recently identified and shown to decrease

rapidly after infection in Ugandan children.[16] In settings where most infections are sub-patent and

fluctuate above or below the detection limit of PCR, detecting the short-lived antibody response in

individuals or households could imply recent infectivity, particularly in the dry season where clinical

cases are rare.

While factors such as the method for determining sero-positivity cut-off values could affect estimates

of sero-prevalence or the magnitude of association between endpoints,[22] the observations in this

study have important implications. In particular, there is a very consistent trend of compound sero-

positivity being a risk factor for asymptomatic infection in contrast to being protective against clinical

malaria. The complex dynamics between clinical and parasitic immunity are not explained through

epidemiological data alone as previous studies have observed lower PCR density in areas of higher

transmission intensity[31] . Fluctuations in sero-positivity levels may be a strong indicator of a persistent

human reservoir of infection, warranting community-targeted interventions if individuals remain

infected but are not clinically apparent and continue to transmit. Household serological status could

be used for targeting interventions where there are foci of asymptomatically infected individuals.

Immuno-epidemiological studies will be subject to variations in antigen-specific antibody dynamics,

as well as the immunogenicity of recombinant antigen constructs. Differences in sequence selection

and expression systems may result in recombinant proteins that differ slightly from natural epitope

morphology. It is unclear the degree to which these subtle variations affect the strength of antibody

detection between recombinant antigens. While this study focuses primarily on total IgG responses,

quantification of antibody levels using a combination of isotypes or subclasses may allow for improved

detection of sero-incidence. For example, IgG3 antibodies are thought to be thought to bind more

weakly than IgG1 and IgG3.[23] Current evidence on the associations of antigen-specific IgG subclasses

with both exposure and immunity to malaria is varied[24,25]. Antigens will fall along a continuum of

suitability as either biomarkers of acute infection to correlates of protective immunity[26], and these

subtleties need to be considered when selecting targets for surveillance. The assays used in this study

have allowed us to quantify antibody responses to specific antigens. Therefore, it will also be valuable

to investigate the optimal combinations of antigens associated with both short-lived and long-lived

antibody responses in surveillance, which could be more routinely used to account for the breadth

of antibody response between individuals in a population.[27–29] Variations such as this could also

potentially be overcome by the use of multiple variants or chimeric antigen constructs.[30]

Changing household sero-prevalence throughout the season may influence the precision of estimates,

which could be overcome with more frequent sampling of serological data, such as three-month

intervals depending on the decay rate of antigen-specific antibodies. Given that household sero-

prevalence may be a robust proxy for past malaria exposure and is simultaneously associated with

increased risk of asymptomatic infections and but reduced risk of clinical malaria (potentially due to

partial immunity), the biological relationship between household serological status and the risk of

clinical or parasitic infection could be further investigated through controlled observational cohort

studies.

These findings indicate that a number of new serological markers of malaria exposure could be useful

for epidemiological surveillance in highly seasonal malaria transmission areas. There is potential for

several of the antigenic targets explored to be used for population-wide screening, all of which have

also been optimised for use on a multiplexed bead-based platform in research settings. Further

translating this to a lateral flow device may offer opportunities for more widespread application if use-

cases can be well established.[32] In light of the strong association between serological status and

increased asymptomatic infection, serological platforms may have direct utility as a screening tool in

active or reactive case detection strategies, most of which have relied on clinical index cases

presenting at health facilities and have shown variability in effectiveness.[33] Future work can also aim

to develop standardised methods for characterising serological responses at the village or cluster level

or as part of randomised trials, while optimal sampling timeframes and sentinel populations can be

designed for use in routine surveillance.

Conclusions

As more countries move towards malaria elimination, including several in sub-Saharan Africa, sensitive

diagnostics will be needed to further understand the dynamics between the parasite, host, and vector

at very low levels of transmission. Integrating newly developed serology markers of recent exposure

into existing field diagnostics will become more important in estimating the human reservoir and

inform targeting of elimination approaches at very low levels of transmission.

List of abbreviations

aOR: Adjusted odds ratio

CI: Confidence interval

DBS: Dried blood spot

EBA175: Erythrocyte binding antigen 175

Etramp5.Ag1: Early transcribed membrane protein 5

GEE: Generalised estimating equations

GEXP18: Gametocyte export protein 18 (GEXP18)

HSP40.Ag1: Heat shock protein 40

IgG: Immunoglobulin

LLIN: Long-lasting insecticide treated net

MDA: Mass drug administration (MDA)

MFI: Median fluorescence intensity

PCD: Passive case detection

PCR: Polymerase chain reaction

Pf, P.falciparum: *Plasmodium falciparum*

*Pf*AMA1: *P.falciparum* apical membrane antigen 1

*Pf*MSP1$_{19}$: *P.falciparum* merozoite surface antigen 1 19-kDa carboxy-terminal region

RDT: Rapid diagnostic test

Rh2.2030: Reticulocyte binding protein homologue 2

URR: Upper River Region, The Gambia

WCR: West Coast Region, The Gambia

<u>Declaration of interests</u>

Ethics approval and consent to participate

This study was approved by the Gambia Government/MRC Joint Ethics Committee (SCC1318). Verbal

consent was first obtained at village sensitisation meetings, followed by individual written informed

consent for all participants. Parents/guardians provided written consent for children less than

17 years, and assent was obtained from children between 12 and 17 years.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding

author on reasonable request.

Competing interests

All authors declare no competing interests.

Funding

This study was funded by the UK Medical Research Council (UKMRC) through the LSHTM Doctoral

Training Programme studentship received by LW. The funders had no role in the design of the study,

collection, analysis, interpretation of data or writing of the manuscript.

Author contributions

LW designed and coordinated the study, supervised and performed serological lab work, analysed the

data, and wrote the manuscript. JM and MA supervised field data collection and laboratory work. SC

and MB conducted the serological assays. KKAT and JB produced the antigens. KKAT and TH developed

the serological assay. JM, MA, UD, IK, and CD advised on study design, interpretation of findings, and

reviewed the manuscript. All authors read and approved the final manuscript.

<u>References</u>

1. Okell, L. C. *et al.* Factors determining the occurrence of submicroscopic malaria infections and

their relevance for control. *Nat. Commun.* **3**, 1237 (2012).

2. Bousema, T., Okell, L., Felger, I. & Drakeley, C. Asymptomatic malaria infections: detectability,

transmissibility and public health relevance. *Nat. Rev. Microbiol.* **12**, 833–40 (2014).

3. Wu, L. *et al.* Comparison of diagnostics for the detection of asymptomatic Plasmodium

falciparum infections to inform control and elimination strategies. *Nature* **528**, S86-93 (2015).

4. Andrews, L. *et al.* Quantitative real-time polymerase chain reaction for malaria diagnosis and

its use in malaria vaccine clinical trials. *Am. J. Trop. Med. Hyg.* **73**, 191–8 (2005).

5. Rockett, R. J. *et al.* A real-time, quantitative PCR method using hydrolysis probes for the

monitoring of Plasmodium falciparum load in experimentally infected human volunteers.

Malar. J. **10**, 48 (2011).

6. Okebe, J. *et al.* School-Based Countrywide Seroprevalence Survey Reveals Spatial

Heterogeneity in Malaria Transmission in the Gambia. *PLoS One* **9**, e110926 (2014).

7. van den Hoogen, L. L. *et al.* Serology describes a profile of declining malaria transmission in

Farafenni, The Gambia. *Malar. J.* **14**, 416 (2015).

8. Drakeley, C. J. *et al.* Estimating medium- and long-term trends in malaria transmission by

using serological markers of malaria exposure. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 5108–13

(2005).

9. Cook, J. *et al.* Serological markers suggest heterogeneity of effectiveness of malaria control

interventions on Bioko Island, equatorial Guinea. *PLoS One* **6**, e25137 (2011).

10.   Biggs, J. *et al.* Serology reveals heterogeneity of Plasmodium falciparum transmission in

northeastern South Africa: implications for malaria elimination. *Malar. J.* **16**, 48 (2017).

11.   Helb, D. A. *et al.* Novel serologic biomarkers provide accurate estimates of recent

Plasmodium falciparum exposure for individuals and communities. *Proc. Natl. Acad. Sci. U. S.*

A. **112**, E4438-47 (2015).

12.   Kerkhof, K. *et al.* Serological markers to measure recent changes in malaria at population

level in Cambodia. *Malar. J.* **15**, 529 (2016).

13.   Mwesigwa, J. *et al.* Residual malaria transmission dynamics varies across The Gambia despite

high coverage of control interventions. *PLoS One* **12**, e0187059 (2017).

14.   Wu, L. *et al.* Optimisation and standardisation of a multiplex immunoassay of diverse

Plasmodium falciparum antigens to assess changes in malaria transmission using sero-

epidemiology. *Wellcome Open Res.* **4**, 26 (2019).

15.   Snounou, G. Genotyping of Plasmodium spp. Nested PCR. *Methods Mol. Med.* **72**, 103–116

(2002).

16.   Helb, D. A. *et al.* Novel serologic biomarkers provide accurate estimates of recent

Plasmodium falciparum exposure for individuals and communities. *Proc. Natl. Acad. Sci. U. S.*

A. **112**, E4438-47 (2015).

17.   Stewart, L. *et al.* Rapid assessment of malaria transmission using age-specific sero-conversion

rates. *PLoS One* **4**, e6083 (2009).

18.   Drakeley, C. J. *et al.* Estimating medium- and long-term trends in malaria transmission by

using serological markers of malaria exposure. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 5108–13

(2005).

19.   Bruce-Chwatt, L. J., Draper, C. C. & Konfortion, P. Seroepidemiological evidence of eradication

445   of malaria from Mauritius. *Lancet (London, England)* **2**, 547–51 (1973).

446 20. Wong, J. *et al.* Serological markers for monitoring historical changes in malaria transmission

447   intensity in a highly endemic region of Western Kenya, 1994-2009. *Malar. J.* **13**, 451 (2014).

448 21. Yman, V. *et al.* Antibody acquisition models: A new tool for serological surveillance of malaria

449   transmission intensity. *Sci. Rep.* **6**, 19472 (2016).

450 22. Irion, A., Beck, H. P. & Smith, T. Assessment of positivity in immuno-assays with variability in

451   background measurements: a new approach applied to the antibody response to Plasmodium

452   falciparum MSP2. *J. Immunol. Methods* **259**, 111–8 (2002).

453 23. Vidarsson, G., Dekkers, G. & Rispens, T. IgG Subclasses and Allotypes: From Structure to

454   Effector Functions. *Front. Immunol.* **5**, (2014).

455 24. Dobaño, C. *et al.* Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175

456   are differentially associated with incidence of malaria in Mozambican children. *Clin. Vaccine*

457   *Immunol.* **19**, 157–66 (2012).

458 25. Tongren, J. E. *et al.* Target antigen, age, and duration of antigen exposure independently

459   regulate immunoglobulin G subclass switching in malaria. *Infect. Immun.* **74**, 257–64 (2006).

460 26. Stanisic, D. I. *et al.* Acquisition of antibodies against Plasmodium falciparum merozoites and

461   malaria immunity in young children and the influence of age, force of infection, and

462   magnitude of response. *Infect. Immun.* **83**, 646–60 (2015).

463 27. Takala, S. L. & Plowe, C. V. Genetic diversity and malaria vaccine design, testing and efficacy:

464   preventing and overcoming 'vaccine resistant malaria'. *Parasite Immunol.* **31**, 560–573

465   (2009).

466 28. Scherf, A., Lopez-Rubio, J. J. & Riviere, L. Antigenic Variation in *Plasmodium falciparum*. *Annu.*

467   *Rev. Microbiol.* **62**, 445–470 (2008).

468 29. Neafsey, D. E. *et al.* Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria

469   Vaccine. *N. Engl. J. Med.* **373**, 2025–2037 (2015).

470 30. Krishnarjuna, B. *et al.* Strain-transcending immune response generated by chimeras of the

471   malaria vaccine candidate merozoite surface protein 2. *Sci. Rep.* **6**, 20613 (2016).

472 31. Mosha, J. F. *et al.* Epidemiology of subpatent Plasmodium falciparum infection: implications

473   for detection of hotspots with imperfect diagnostics. *Malar. J.* **12**, 221 (2013).

474 32. Greenhouse, B. *et al.* Priority use cases for antibody-detecting assays of recent malaria

475   exposure as tools to achieve and sustain malaria elimination. *Gates Open Res.* **3**, 131 (2019).

476 33. Hsiang, M. S. *et al.* Active Case Finding for Malaria: A 3-Year National Evaluation of Optimal

477   Approaches to Detect Infections and Hotspots Through Reactive Case Detection in the Low-

478   transmission Setting of Eswatini. *Clin. Infect. Dis.* (2019). doi:10.1093/cid/ciz403

491 **Table 1. Serology sample size. Number of compounds and individuals by village and survey month.**

	Compounds	Individuals			
West Coast Region		**July 2013**	**December 2013**	**April 2014**	**December 2014**
Besse	69	401	388	-	-
N'Demban	24	136	138	-	-
Subtotal WCR	93	537	526	-	-
Upper River Region					
Njaiyal	28	382	181	298	286
Madina Samako	43	397	451	525	471
Subtotal URR	71	779	632	823	757
Total	164	1316	1158	823	757

493 **Table 2. Study subject characteristics by region and survey month, n (%) out of total individual in monthly**
494 **survey**

West Coast Region	**July 2013**	**December 2013**	**April 2014**	**December 2014**
Gender			-	-
Male	240 (46.3)	227 (45.0)		
Female	278 (53.7)	277 (55.0)	-	-
Age category				
<5 years	112 (21.5)	104 (20.5)	-	-
5 -15 years	188 (36.1)	195 (38.5)	-	-
>15 years	221 (42.4)	208 (41.0)	-	-
LLIN use 24hr	519 (96.6)	492 (94.3)	-	-
Upper River Region	**July 2013**	**December 2013**	**April 2014**	**December 2014**
Gender				
Male	371 (47.9)	287 (45.7)	401 (49.0)	359 (47.5)
Female	404 (52.1)	341 (54.3)	417 (51.0)	396 (52.5)
Age category				
<5 years	164 (21.5)	144 (23.3)	186 (23.0)	175 (23.6)
5 -15 years	260 (34.1)	234 (37.8)	304 (37.6)	258 (34.9)
>15 years	339 (44.4)	241 (38.9)	318 (39.4)	307 (41.5)
LLIN use 24hr	278 (46.6)	245 (41.7)	301 (43.8)	283 (46.2)

Table 3. Regional sero-prevalence (ages 2-10 years) by antigen and all-age incidence rates for clinical malaria and *Pf* infection. Mean sero-prevalence (%) and incidence rates with 95%CI shown in parentheses.

	West Coast Region (WCR)		Upper River Region (URR)	
	July 2013	December 2013	July 2013	December 2013
Clinical incidence rate	0.08 (0.04 - 0.21)	0.14 (0.04 - 0.44)	0.13 (0.04 - 0.39)	0.21 (0.1 - 0.51)
Pf infection rate	0.23 (0.13 - 0.39)	0.67 (0.40 - 1.13)	0.56 (0.42 - 0.74)	2.87 (2.36 - 3.50)
Sero-prevalence (ages 2-10 years)				
Etramp5.Ag1	4.8% (1.9 - 7.8)	13.7% (8.9 - 18.5)	8.7% (5.4 - 12.1)	33.6% (27.6 - 39.6)
GEXP18	12.6% (8.0 – 17.1)	12.7% (8.0 – 17.3)	25.1% (20.0 – 30.2)	36.1% (30.0 – 42.2)
HSP40.Ag1	6.3% (3.0 - 9.6)	6.1% (2.8 - 9.4)	8.4% (5.1 - 11.6)	24.1% (18.7 - 29.5)
Rh2.2030	1.4% (0.0 - 3.1)	1.0% (0.0 - 2.4)	9.8% (6.3 - 13.3)	25.3% (19.8 - 30.8)
EBA175	1.9% (0.1 - 3.8)	1.0% (0.0 - 2.4)	7.3% (4.2 - 10.3)	15.8% (11.2 - 20.4)
*Pf*MSP1$_{19}$	3.4% (0.9 - 5.8)	8.1% (4.3 - 11.9)	5.1% (2.5 - 7.7)	22.0% (16.8 - 27.2)
*Pf*AMA1	4.8% (1.9 - 7.8)	4.1% (1.3 - 6.8)	17.8% (13.3 - 22.3)	33.2% (27.2 - 39.1)

Table 4. Pearson's correlation coefficients between regional sero-prevalence (ages 2-10 years) and all-age incidence rates for clinical malaria and *Pf* infection. Correlation estimates are based on data from the West Coast Region (WCR) and Upper River Region (URR) in July and December 2013. Correlations excluding data from URR December 2013 are shown in brackets.

	Pearson's correlation coefficient	
Antigen	Sero-prevalence vs. Clinical incidence rate	Sero-prevalence vs. *Pf* infection incidence rate
Etramp5.Ag1	0.98 [0.96]	0.98 [0.98]
GEXP18	0.90 [0.69]	0.84 [0.63]
HSP40.Ag1	0.95 [0.85]	0.99 [0.81]
EBA175	0.87 [0.40]	0.91 [0.32]
Rh2.2030	0.88 [0.39]	0.94 [0.31]
*Pf*MSP1$_{19}$	0.97 [0.96]	0.99 [0.98]
*Pf*AMA1	0.87 [0.48]	0.89 [0.40]

Table 5. Odds of clinical malaria and asymptomatic infection by individual serological status, unadjusted and adjusted for age group (<5 years, 5-15 years, and > 15 years) and LLIN use in the last 24 hours.

Odds of clinical malaria or asymptomatic infection amongst sero-positive individuals, by antigen						
	Unadjusted			**Adjusted**		
	OR	**95%CI**	**p-value**	**aOR**	**95%CI**	**p-value**
Etramp5.Ag1						
Clinical malaria	5.50	3.33 - 9.07	<0.001	4.56	2.94 - 7.06	<0.001
Asymptomatic infection	3.24	2.67 – 3.94	<0.001	3.36	2.75 - 4.11	<0.001
GEXP18						
Clinical malaria	2.40	1.38 - 4.18	0.002	1.40	0.85 - 2.31	0.182
Asymptomatic infection	2.99	2.43 - 3.68	<0.001	3.10	2.50 - 3.85	<0.001
HSP40.Ag1						
Clinical malaria	1.63	0.91 - 2.90	0.099	0.97	0.58 - 1.61	0.903
Asymptomatic infection	2.57	2.11 - 3.13	<0.001	2.66	2.14 - 3.31	<0.001
Rh2.2030						
Clinical malaria	2.08	1.08 - 4.01	0.029	1.13	0.66 - 1.93	0.662
Asymptomatic infection	2.51	2.04 - 3.10	<0.001	3.10	2.44 - 3.94	<0.001
EBA175						
Clinical malaria	1.32	0.66 - 2.66	0.431	1.19	0.65 - 2.17	0.574
Asymptomatic infection	2.13	1.77 – 2.56	<0.001	2.68	2.09 - 3.94	<0.001
*Pf*MSP1$_{19}$						
Clinical malaria	3.54	1.88 - 6.69	<0.001	3.82	2.41 - 6.04	<0.001
Asymptomatic infection	2.33	1.87 - 2.92	<0.001	2.50	1.93 - 3.24	<0.001
*Pf*AMA1						
Clinical malaria	2.20	1.26 - 3.86	0.006	2.18	1.23 - 3.84	0.007
Asymptomatic infection	2.66	2.16 - 3.29	<0.001	3.83	2.95 - 4.98	<0.001

Table 6. Odds of clinical malaria and asymptomatic *Pf* infection by compound serological status. Estimates are weighted by compound size and shown as unadjusted odds ratios (OR) and adjusted odds ratios (aOR) for age group (<5 years, 5-15 years, and > 15 years).

Odds of clinical malaria or asymptomatic *Pf* infection for individuals residing in sero-positive compounds						
	Unadjusted			Adjusted		
	OR	95%CI	p-value	aOR	95%CI	p-value
Etramp5.Ag1						
Clinical malaria	0.18	0.03 - 1.00	0.050	0.17	0.03 - 0.84	0.030
Asymptomatic infection	2.91	1.66 - 5.12	<0.001	2.95	1.66 - 5.24	<0.001
GEXP18						
Clinical malaria	0.12	0.02 - 0.84	0.032	0.11	0.02 - 0.68	0.017
Asymptomatic infection	2.74	1.61 - 4.67	<0.001	2.71	1.58 - 4.63	<0.001
HSP40.Ag1						
Clinical malaria	0.13	0.02 - 0.76	0.023	0.12	0.02 - 0.66	0.015
Asymptomatic infection	1.35	0.78 - 2.34	0.281	1.42	0.81 - 2.48	0.226
Rh2.2030						
Clinical malaria	0.07	0.01 - 0.46	0.006	0.06	0.01 - 0.33	0.001
Asymptomatic infection	1.73	0.97 - 3.06	0.062	1.96	1.12 - 3.44	0.019
EBA175						
Clinical malaria	0.07	0.01 - 0.58	0.014	0.07	0.01 - 0.54	0.011
Asymptomatic infection	1.04	0.53 - 2.05	0.915	1.06	0.53 - 2.13	0.875
***Pf*MSP1$_{19}$**						
Clinical malaria	0.15	0.03 - 0.83	0.030	0.11	0.03 - 0.48	0.003
Asymptomatic infection	1.92	1.17 - 3.14	0.010	2.00	1.21 - 3.29	0.007
***Pf*AMA1**						
Clinical malaria	0.06	0.01 - 0.56	0.014	0.05	0.01 - 0.47	0.009
Asymptomatic infection	2.01	1.03 - 3.91	0.040	2.04	1.03 - 4.03	0.041

Figures

Figure 1. Map of Malaria Transmission Dynamics Study with regions and study villages by PCR prevalence.

Figure 2. Pearson's correlation between regional sero-prevalence (ages 2-10 years) and all-age incidence rates for clinical malaria and *Pf* infection. Correlations between sero-prevalence and incidence rates for clinical malaria (new clinical episodes divided by person-years at risk) in red and *Pf* infection (new PCR infections divided by person-years at risk) In blue were based on data from the West Coast Region (WCR) and the Upper River Region (URR) in July and December 2013. Correlations excluding data from URR December 2013 shown in brackets.

Figure 3. Odds clinical malaria and asymptomatic infection by a) individual sero-positivity status b) residing in the same compound as a sero-positive individual. Analyses is adjusted for age group (<5 years, 5-15 years, and >15 years) and LLIN use in the last 24 hours and weighted by compound size.

Figure 4. Odds of clinical malaria by compound sero-prevalence (a) and odds of asymptomatic infection by compound sero-prevalence (b). Analyses is adjusted for age group (<5 years, 5-15 years, and >15 years) and LLIN use in the last 24 hours and weighted by compound size.

Figure 5. Household geolocation of Etramp5. Ag1 sero-positive, clinical malaria and *Pf* infections across four villages. Spatial distribution of infections shown for lower transmission (N'demban) and higher transmission (Besse) villages in the West Coast Region (WCR) and lower transmission (Njaiyal) and higher transmission (Madina Samako) villages in the Upper River Region (URR). Infections at the start of the wet season (June – July 2013) shown on the left and during the wet and transmission season (August – December 2013) on the right.

Additional files

Supplementary 1. Sero-prevalence amongst individuals aged 2 - 10 year and prevalence of sero-
positive compounds.

Supplementary 2. Odds of clinical malaria and asymptomatic infection for sero-positive individuals
and individuals residing in sero-positive compounds. Unadjusted and adjusted odds ratios for seven
malaria antigenic targets - Etramp5.Ag1, GEXP18, HSP40.Ag1, Rh2.2030, EBA175, PfMSP1$_{19}$, and
PfAMA1

Supplementary 3. Map of household geolocation of PfAMA1 sero-positive, clinical malaria and Pf
infections across four villages during dry and wet transmission seasons. Spatial distribution of
infections shown for lower transmission (N'demban) and higher transmission (Besse) villages in the
West Coast Region (WCR) and lower transmission (Njaiyal) and higher transmission (Madina Samako)
villages in the Upper River Region (URR). Infections at the start of the wet season (June – July 2013)
shown on the left and during the wet and transmission season (August – December 2013) on the right.